Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash from Investing Activities: 2010-2025

Historic Cash from Investing Activities for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to -$10000.0.

  • OptimizeRx's Cash from Investing Activities rose 8913.04% to -$10000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$222000.0, marking a year-over-year increase of 5403.73%. This contributed to the annual value of -$450000.0 for FY2024, which is 9822.39% up from last year.
  • Per OptimizeRx's latest filing, its Cash from Investing Activities stood at -$10000.0 for Q3 2025, which was up 8913.04% from -$44000.0 recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Cash from Investing Activities registered a high of $3.2 million during Q2 2023, and its lowest value of -$37.5 million during Q3 2022.
  • In the last 5 years, OptimizeRx's Cash from Investing Activities had a median value of -$120000.0 in 2024 and averaged -$4.5 million.
  • As far as peak fluctuations go, OptimizeRx's Cash from Investing Activities tumbled by 2242542.61% in 2022, and later skyrocketed by 25201.52% in 2023.
  • OptimizeRx's Cash from Investing Activities (Quarter) stood at -$99021.0 in 2021, then tumbled by 18567.26% to -$18.5 million in 2022, then tumbled by 40.66% to -$26.0 million in 2023, then skyrocketed by 99.54% to -$120000.0 in 2024, then soared by 91.67% to -$10000.0 in 2025.
  • Its Cash from Investing Activities was -$10000.0 in Q3 2025, compared to -$44000.0 in Q2 2025 and -$84000.0 in Q1 2025.